By: hreeya Nanda From: medwirenews.com Exploratory data from the MINDACT trial suggest that women older than 50 years who have high clinical risk but low genomic risk according to the 70-gene MammaPrint signature may be able to forgo adjuvant chemotherapy for early-stage breast cancer. By contrast, “in younger women, a potentially clinically relevant chemotherapy benefit of about 5 percentage points is …
Perception critical to women’s breast reconstruction decision making
Source: Queensland University of Technology From: eurekalert.org The largest ever behavioral study of breast surgeons, breast care nurses and former or current breast cancer patients reveals surgeons have more say than patients on reconstructive surgery options When women undergo surgical treatment for breast cancer, they often also have reconstructive surgery but new QUT research reveals many women feel left out …
The Financial Burden of Breast Cancer
From: breastadvocateapp.com One in every 8 women in the US will be diagnosed with breast cancer in her lifetime, and 2,000 men will be diagnosed with breast cancer this year. Treatment options, new drugs, surgical advances and breast reconstruction options are all commonly discussed within the breast cancer community. A topic that is not discussed enough is the financial burden, or …
Let’s Talk About End-of-Life Care
From: Journal of the National Comprehensive Cancer Network A new study published in JNCCN — Journal of the National Comprehensive Cancer Network finds a vast majority of patients would like their doctor to ask them about their preferences for end-of-life care. This is at odds with the fact that the survey also revealed that less than 10 percent had spoken …